What Altuzan Treats: Main Uses and Benefits

Altuzan (bevacizumab) is an essential element of therapeutic management generally used for managing several types of advanced, recurrent, or metastatic solid tumors in adults, often in combination with other anti-cancer therapies. This treatment is applied across a range of oncologic domains and may be used to support patient stability during treatment.

---

This medication is commonly used to treat conditions involving systemic or localized discomfort from cancers that have spread (metastatic), including those of the colon and rectum, non-squamous lung cancer, kidney (renal cell carcinoma), and liver (hepatocellular carcinoma). It is also considered relevant in recurrent or persistent carcinoma of the cervix and various stages of advanced ovarian, fallopian tube, and primary peritoneal cancers.

The treatment contributes to potential disease control and is considered relevant for easing the progression of the condition. In aggressive brain tumors like recurrent glioblastoma, it may assist with managing symptoms linked to organ-specific functional stress.

“This intervention provides supportive relief that helps ease the overall burden of symptoms and assists with maintaining functional stability during difficult symptomatic episodes.”

Quick Fact: Therapeutic Support
Symptom Domain	Symptoms linked to organ-specific functional stress (e.g., neurological activity due to swelling).
Condition Focus	Advanced, recurrent, or metastatic malignancies (e.g., mCRC, NSCLC, rGBM).
Primary Benefit	Offers symptomatic relief that helps patients cope more steadily and assists with maintaining functional stability.

Who Can and Cannot Use Altuzan? (Official Regulatory Information)

Eligibility for Altuzan (bevacizumab) is strictly governed by patient characteristics and clinical status, as defined in official regulatory labeling (e.g., FDA, EMA).

Contraindicated Populations (Must Not Use):

• Patients with known hypersensitivity to bevacizumab or any of its excipients.
• Patients with a history of allergy to Chinese Hamster Ovary (CHO) cell products or other recombinant humanized antibodies.
• Pregnant patients are absolutely prohibited from using the medicine.
• Patients with untreated Central Nervous System (CNS) metastases (as defined by certain regulators).

Age-Group Eligibility Rules:

Age Group	Regulatory Status
Children & Adolescents (<18)	Safety and efficacy have not been established; no relevant use is recognized for the approved cancer indications.
Adults (≥18)	Approved population; no dose adjustment is typically required for older adults (≥65), though caution is advised due to an increased risk of arterial thromboembolic events.

Key Use Limitations and Restrictions:

• Surgery and Wounds: Treatment must not be initiated for at least 28 days following major surgery and until the surgical wound is completely healed.
• Pregnancy/Lactation: Females of reproductive potential must use effective contraception during therapy and for 6 months after the final dose. Breastfeeding is not recommended during treatment and for 6 months after the last dose.
• Severe Complications: Therapy must be permanently discontinued if the patient develops complications such as a Gastrointestinal (GI) perforation, a Grade 4 fistula, a severe hemorrhage, or a severe arterial thromboembolic event.

Interactions involving Altuzan (bevacizumab) are primarily governed by pharmacodynamic effects and mandatory administration timing rules, rather than the metabolic or transporter-based interactions common to small-molecule drugs.

Drug-Drug Interaction Patterns

Official regulatory documents classify the interaction profile of bevacizumab as being without significant effect on the systemic exposure of many co-administered antineoplastic agents. Studies have confirmed that Altuzan does not alter the pharmacokinetics—such as clearance or area under the curve—of widely used chemotherapy medicines like irinotecan, cisplatin, or paclitaxel. This is consistent with bevacizumab's nature as a monoclonal antibody, which does not rely on the Cytochrome P450 (CYP) enzyme system for metabolism.

However, specific combination therapies are subject to regulatory restrictions due to pharmacodynamic concerns. The co-administration of bevacizumab with the Tyrosine Kinase Inhibitor sunitinib for metastatic renal cell carcinoma is not recommended in official guidance due to documented reports of increased toxicities. Similarly, the combination with panitumumab plus chemotherapy for metastatic colorectal cancer is also generally not recommended.

Administration Timing Restriction

A mandatory restriction exists concerning surgical procedures. Altuzan must be withheld for a minimum of 28 days prior to any elective surgical procedure. Following major surgery, treatment must not be resumed until at least 28 days have passed or until the surgical wound is fully and completely healed, a rule established due to the documented potential for delayed or complicated wound healing. Official regulatory labels do not document specific interactions with food, alcohol, or herbal products.

Targeted Neutralization of VEGF-A

Altuzan (Bevacizumab) is a monoclonal antibody engineered as a ligand-sequestering agent, binding with high affinity to the soluble signaling protein Vascular Endothelial Growth Factor A (VEGF-A). By neutralizing VEGF-A, the drug prevents this key molecule from binding to its receptors (VEGFR-1 and VEGFR-2) on endothelial cells. This interaction blocks the initiation of the pro-angiogenic pathway at its source, thereby suppressing the key signal that promotes vascular cell proliferation and survival.

Induction of Microvascular Regression

The functional blockade of the VEGF signaling pathway interrupts the cellular communication that drives the proliferation of new blood vessels, a process known as angiogenesis. When essential survival signals from VEGF-A are withdrawn, endothelial cells that form the structure of the abnormal microvessels undergo apoptosis (programmed cell death). This cellular consequence leads to the regression of existing abnormal microvessels, resulting in a physiological decrease in microvessel density.

Systemic Vascular Function Modulation

Bevacizumab's mechanism includes systemic effects due to VEGF-A's critical role in maintaining healthy vascular function. Its generalized inhibition interferes with VEGF-A’s ability to sustain normal vascular tone and blood vessel integrity by affecting nitric oxide production. This systemic interference with vascular regulation can lead to increased peripheral resistance and physiological consequences like changes in blood pressure; these are direct physiological consequences of generalized VEGF-A blockade.

How Altuzan (Bevacizumab) is Used

Altuzan is administered through specific procedures to ensure delivery in a clinical setting. As a concentrate, the medicine must be exclusively administered via Intravenous (IV) Infusion; injection methods such as IV push or bolus are explicitly prohibited.

---

Dosing and Preparation Protocol

Altuzan is dosed based on the patient's body weight, with standard regimens typically ranging from 5 mg/kg to 15 mg/kg, depending on the specific approved use. The treatment follows a cyclic schedule, with infusions scheduled either every 2 weeks (q2w) or every 3 weeks (q3w).

Prior to administration, the prescribed amount of concentrate must be diluted in 100 mL of 0.9% Sodium Chloride Injection (Normal Saline). It is a key procedural restriction that the product must not be mixed with or administered alongside glucose solutions.

---

Infusion Schedule and Treatment Duration

The time taken for the IV infusion is titrated across the first three doses. The initial infusion is given over 90 minutes. If tolerated, the second dose is administered over 60 minutes, and all subsequent infusions are typically given over 30 minutes.

Treatment is intended to be a long-term course, generally continuing until evidence of disease progression or until a predefined, maximum number of cycles is reached, such as in certain ovarian cancer regimens. For procedural safety, the initiation of Altuzan is delayed until at least 28 days following major surgery and until the surgical wound is fully healed. Dose reduction for adverse events is not recommended; instead, therapy is temporarily suspended or permanently discontinued.

Research Evidence / Overview of Studies for Altuzan (Bevacizumab)

This section provides a factual overview of the types of research and clinical studies—primarily large-scale randomized controlled trials (RCTs)—that regulators use to assess Altuzan (bevacizumab). It summarizes the scope of the evidence for specific indications, the outcomes studied, and areas where research remains limited, without offering medical advice. The findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

---

Evidence for use in Metastatic Colorectal Cancer (mCRC)

Research for metastatic colorectal cancer involves multiple large Phase III RCTs. Studies examined the combination of the medicine with chemotherapy, and findings reported statistically significant differences in both Overall Survival (OS) and Progression-Free Survival (PFS). Uncertainty remains regarding how these findings apply to very small, specific molecular subgroups within colorectal cancer.

Evidence for use in Advanced Non-Squamous Lung Cancer

The evidence base for advanced non-squamous non-small cell lung cancer (NSCLC) is anchored by pivotal Phase III RCTs. Research explored outcomes such as OS and PFS, and trials described the finding of statistically significant differences in these endpoints when the medicine was observed in the combination regimen. The initial research generally excluded patients with tumors having predominantly squamous cell histology.

Evidence for use in Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

For these gynecological cancers, Phase III RCTs evaluated the medicine across newly diagnosed and recurrent settings, measuring PFS and OS. Studies report patterns where statistically significant differences were measured in the PFS endpoint, but findings for the OS endpoint were described as inconsistent across studies.

Evidence for use in Advanced Renal Cell Carcinoma (mRCC) and Recurrent Glioblastoma (rGBM)

Evidence for other indications, such as advanced renal cell carcinoma and recurrent glioblastoma, is often based on Phase II or non-controlled studies. Research for these indications reported measured differences in Progression-Free Survival (PFS), but conclusive findings for the Overall Survival (OS) endpoint are often limited or not consistently established.

Evidence in Specific Patient Groups and Areas of Research Uncertainty

Research has monitored patterns in specific adult subgroups, including older patients and those with differing general health statuses. These results apply only to the populations studied. A key area of research uncertainty is the Overall Survival endpoint, which has mixed or non-significant findings in specific combination regimens and disease settings, demonstrating that evidence quality varies across the studied indications.

Key Studies & References

1. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis
2. Avastin (bevacizumab) Prescribing Information

Common questions about Altuzan (FAQ)

Q: How long does Altuzan stay in the body after a treatment?

A: Studies reported in the official product information indicate that the active ingredient, bevacizumab, has a long half-life. The estimated terminal half-life is around 20 days (range 11–50 days). Based on pharmacokinetics, the drug’s concentration in the body is expected to maintain near-maximum levels for about three months.

---

Q: Can Altuzan be used for types of cancer not listed in the main uses?

A: Regulatory documents only confirm the safety and efficacy of bevacizumab for its approved indications, such as certain types of metastatic colorectal, lung, and ovarian cancers. The official scope of use is limited to these specific conditions.

---

Q: Is Altuzan the same as the drug 'Avastin'?

A: The active ingredient in Altuzan is bevacizumab. This same active ingredient is also marketed under the brand name Avastin in many regions. Altuzan and Avastin contain the same medicine, but may be used in different global markets.

---

Q: Is Altuzan considered an immunotherapy drug?

A: The official product information classifies bevacizumab as an Antineoplastic Agent and a Vascular Endothelial Growth Factor (VEGF) Inhibitor. Its primary function is anti-angiogenesis (disrupting blood vessel growth) by binding to VEGF-A. Official classifications define it as a type of targeted therapy, which is a different category than most drugs commonly referred to as immunotherapy.

---

Q: Can side effects from Altuzan appear long after the treatment?

A: Because of the drug’s long half-life, the official product information mandates that certain safety precautions, such as the use of contraception for women, must be continued for six months after the last dose. This duration is a reflection of the drug's activity extending well beyond the final administration day.

---

Q: Does Altuzan interact with common pain relievers like ibuprofen?

A: The official label does not specifically list common pain relievers like ibuprofen. However, combining these medicines may potentially increase the risk of certain complications, as both can affect the gastrointestinal system. Regulatory guidance requires that healthcare providers are informed of all medicines being taken.

---

Q: Are there any vitamins or supplements that should be avoided while on Altuzan?

A: Official regulatory labels generally do not document specific interactions with vitamins or non-herbal supplements. However, official guidance requires that all healthcare providers be informed of all products being used during treatment.

---

Q: Can Altuzan interact with medicines for high blood pressure?

A: Since Altuzan can cause high blood pressure, anti-hypertensive medications may be used to manage this side effect. Any adjustments to high blood pressure medication should be determined by a healthcare provider after close monitoring.

---

Q: Can Altuzan be given to people with heart problems?

A: Official documents list warnings regarding the risk of Arterial Thromboembolic Events (such as stroke or heart attack) and Congestive Heart Failure. Patients with a prior history of heart or vascular conditions may be at increased risk of these side effects. Therefore, the decision to use the medicine requires careful assessment of the patient's condition by a healthcare provider.

---

Q: Can Altuzan be used by people with kidney issues?

A: Pre-existing kidney issues are not listed as an absolute contraindication in official documents. However, since the drug is associated with potential kidney-related side effects, such as proteinuria and Nephrotic Syndrome, close monitoring of kidney function is a required component of treatment.

---

Q: When does the full effect of Altuzan treatment typically begin?

A: Based on the drug's long half-life (around 20 days), the concentration of the medicine in the body is predicted to reach a steady-state after approximately 84 days or three months of treatment. Steady-state is the point where the drug's intake and elimination are balanced.

---

Q: Are there ongoing studies related to the use of Altuzan?

A: Governmental resources, such as the NIH Clinical Trials Register, document numerous ongoing clinical trials that are currently investigating bevacizumab. These studies continue to explore the drug’s use in various indications and in combination with other treatment regimens.

---

Q: Has Altuzan been approved in many countries around the world?

A: Yes, bevacizumab is a widely approved medicine. Regulatory agencies in the United States, Europe, Australia, and Canada have all authorized its use for specific cancer indications. It is also listed on the WHO Model List of Essential Medicines, which confirms its broad availability and use.

---

Q: Why is Altuzan administered by a healthcare professional?

A: Altuzan is a prescription-only biologic that must be administered only via Intravenous (IV) Infusion. This is mandatory because of the risk of potentially severe adverse reactions, including Infusion-Related Reactions. Administration must occur in a clinical setting where trained personnel can provide the necessary immediate monitoring.

---

Q: What are the risks associated with the infusion process of Altuzan?

A: The regulatory label documents a risk of Infusion-Related Reactions, which may occur during or shortly after the treatment is given. These reactions, often seen with the first dose, can include symptoms such as severe high blood pressure, difficulty breathing, or headache. The symptoms of these reactions necessitate careful patient observation during administration.

---

Q: Does Altuzan change your appetite?

A: Official reports of adverse reactions from clinical trials included a decrease in appetite, medically known as anorexia, in a percentage of patients. This is listed as one of the reported non-serious side effects.

---

Q: Does Altuzan change your vision?

A: The regulatory label lists a potential risk for a rare condition called Reversible Posterior Leukoencephalopathy Syndrome (PRES). Symptoms associated with PRES can include visual disturbances. If a patient experiences visual disturbances, they should be reported to their healthcare provider.

---

Q: Can people taking Altuzan receive vaccines?

A: The product label does not list a specific contraindication for vaccines when Altuzan is used alone. However, an increased risk of infection is a potential consideration in patients receiving Altuzan in combination with chemotherapy.

---

Q: Does Altuzan affect fertility in men or women?

A: The drug may increase the risk of ovarian failure and therefore may impair female fertility; the long-term effects on fertility are currently unknown. The product label does not document a specific effect on male fertility.

---

Q: Does Altuzan interact with over-the-counter cold medicines?

A: The official label does not specifically address non-prescription cold medicines. However, because some cold medicines can affect blood pressure, a healthcare provider should be informed of all over-the-counter products being taken, especially since Altuzan is associated with a risk of high blood pressure.

The storage and disposal of Altuzan (bevacizumab) concentrate must strictly follow official regulatory requirements.

Requirement	Official Statement
Storage Temperature	Store refrigerated at 2 C to 8 C (36 F to 46 F).
Protection	Keep in the original carton and protected from light. Do not freeze and do not shake the vial.
Stability (Diluted)	The diluted solution may be stored at 2 C to 8 C for up to 8 hours.
Handling Restriction	The product must not be mixed with dextrose solutions.
Disposal	As a preservative-free, single-dose product, any unused portion remaining in the vial must be discarded. Disposal of all unused medicine must be done according to local pharmaceutical waste regulations.
Child Safety	Keep out of the sight and reach of children.